Novartis Ag (NVS) 80.36 $NVS Alcon launches the

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novartis Ag (NVS) 80.36 $NVS

Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience
Globe Newswire - 2 hrs 3 mins ago
Novartis International AG / Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
ACCESSWIRE - Wed Sep 07, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 7, 2016 / Active Wall St. announces its post-earnings coverage on The Cooper Companies Inc. (NYSE: COO). The company released its financial results for the fiscal third quarter 2016 (Q3 FY16) on September 1, 2016. The Contact-lens company updated its financial guidance after stellar earnings results. Register with us now for your free membership at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), VRX: 30.27 (+0.80), COO: 188.56 (+0.26), NVS: 80.36 (+0.21), VRX.TO: 39.05 (+1.19)

Influenza Market 2015-2020: Global Industry Perspective, Comprehensive Analysis and Forecasts Featuring AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur - Research and Markets
BusinessWire - Wed Sep 07, 3:35AM CDT
Research and Markets has announced the addition of the "Influenza Market (H1N1 Vaccines and Others) by Product (Influenza Vaccines and Influenza Drugs): Global Industry Perspective, Comprehensive Analysis and Forecast 2014 - 2020" report to their offering.
NVS: 80.36 (+0.21)

Foundation Fighting Blindness Sponsors Presentation by Retina Specialist James M. Maisel, M.D. on Macular Degeneration and Hereditary Retinal Degeneration
PRWeb - Wed Sep 07, 3:03AM CDT
James Maisel, MD will present "Macular Degeneration and Hereditary Retinal Degeneration" for the Foundation Fighting Blindness, Long Island Chapter Speaking Series, on September, 2016, 1:30-3:00 pm at the Farmingdale Public Library. The presentation is free to the public.
AGN: 238.42 (-0.70), NVS: 80.36 (+0.21)

Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:38AM CDT
Novartis Pharma AG (NVS) announced positive results from a head-to-head study, FLAME, on COPD drug Ultibro Breezhaler.
ANIP: 60.71 (-0.84), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), NVS: 80.36 (+0.21)

Pharmaceutical Products and CMO Market is Expanding at a CAGR 11.6% by 2024; Improving Regulatory Scenario Across Latin America Market: Transparency Market Research
PR Newswire Europe - Tue Sep 06, 8:31AM CDT
ALBANY, New York, September 6, 2016 /PRNewswire/ --
PFE: 34.84 (+0.07), NVS: 80.36 (+0.21)

Brazilian Pharmaceutical Market Outlook 2016-2026
PR Newswire Europe - Tue Sep 06, 8:03AM CDT
LONDON, September 6, 2016 /PRNewswire/ --
NVS: 80.36 (+0.21)

ROX Medical Raises $40M Financing
PR Newswire Europe - Tue Sep 06, 12:01AM CDT
ROX Medical, a privately held clinical-stage medical device company developing technologies for hypertension, announced today that it has secured $40M in Series E financing. Novartis Venture Fund and Apple Tree Partners led the round, joined by previous investors Versant Ventures and Domain Associates.
NVS: 80.36 (+0.21)

Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets
BusinessWire - Mon Sep 05, 10:12AM CDT
Research and Markets has announced the addition of the "Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016" clinical trials to their offering.
NVS: 80.36 (+0.21)

Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups
Globe Newswire - Sat Sep 03, 12:15AM CDT
Novartis International AG / Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), ARRY: 3.60 (unch), NVS: 80.36 (+0.21)

Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.87 (-0.37), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), BMY: 56.57 (-0.39), NVS: 80.36 (+0.21)

Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)

Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)

AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment
Globe Newswire - Wed Aug 31, 12:15AM CDT
Novartis International AG / AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Globe Newswire - Tue Aug 30, 3:01PM CDT
Novartis International AG / FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)

Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 238.42 (-0.70), GNRX: 24.86 (+0.46), PRGO: 90.39 (-1.68), AXGN: 9.00 (+0.06), AKRX: 26.69 (+0.23), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), AMPH: 19.03 (+0.12), NVS: 80.36 (+0.21)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading